[Significance of the PSA-concentration for the Detection of Prostate Cancer]

Overview

Journal Pathologe

Specialty Pathology

Date 2005 Oct 1

PMID 16195861

Citations 1

Authors

A Stachon

Affiliations

Soon will be listed here.

Abstract

Prostate cancer among adult males is the most common neoplasm in western countries. Prostate specific antigen (PSA) is now a well established tumor marker that aids in the early detection of localized prostate cancer. Increased PSA concentrations are found in the serum of patients with benign prostatic hyperplasia or patients with prostate cancer, respectively. Therefore, in general the specificity of this test is low. The diagnostic value of PSA can be improved in consideration of clinical data, patients age, the measurement of free or complexed PSA, and the measurement of PSA velocity, respectively. Furthermore, there is a high variability between commercial PSA assays. Finally, the pre-analytical laboratory procedures have a high impact on the PSA measurement.

Citing Articles

Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study.

Tai S, Huang S, Bao B, Wu M Sci Rep. 2016; 6:29606.

PMID: 27387675 PMC: 4937372. DOI: 10.1038/srep29606.

References

Okihara K, Cheli C, Partin A, Fritche H, Chan D, Sokoll L . Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol. 2002; 167(5):2017-23; discussion 2023-4. DOI: 10.1016/s0022-5347(05)65075-6. View

Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A . Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19):1542-7. DOI: 10.1001/jama.279.19.1542. View

Schaid D . The complex genetic epidemiology of prostate cancer. Hum Mol Genet. 2004; 13 Spec No 1:R103-21. DOI: 10.1093/hmg/ddh072. View

Jain S, Bhojwani A, Mellon J . Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. Postgrad Med J. 2002; 78(925):646-50. PMC: 1742550. DOI: 10.1136/pmj.78.925.646. View

Oberpenning F, Schmid H, Hertle L, Semjonow A . The impact of intraoperative manipulation of the prostate on total and free prostate-specific antigen. Int J Biol Markers. 2002; 17(3):154-60. DOI: 10.1177/172460080201700302. View

Schmid H, Stamey T, McNeal J, Freiha F, Redwine E, Whittemore A . [Effect of the natural history on management of adenocarcinoma of the prostate]. Urologe A. 1994; 33(2):144-8. View

Christensson A, LAURELL C, Lilja H . Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194(3):755-63. DOI: 10.1111/j.1432-1033.1990.tb19466.x. View

Jung K, Stephan C, Lein M, Henke W, Schnorr D, Brux B . Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem. 1996; 42(7):1026-33. View

Schroder F, Wildhagen M . Low levels of PSA predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging. Urology. 2002; 59(3):462. DOI: 10.1016/s0090-4295(01)01581-3. View

10.

Oesterling J, Jacobsen S, Chute C, Guess H, Girman C, Panser L . Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993; 270(7):860-4. View

11.

Carter H, Pearson J, Metter E, Brant L, Chan D, Andres R . Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992; 267(16):2215-20. PMC: 3461837. View

12.

Virtanen A, Gomari M, Kranse R, Stenman U . Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem. 1999; 45(7):987-94. View

13.

Vashi A, Wojno K, Henricks W, England B, Vessella R, Lange P . Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology. 1997; 49(1):19-27. DOI: 10.1016/S0090-4295(96)00511-0. View

14.

Schroder F, de Koning H, Vis A, Hoedemaeker R, Kranse R . Prostate cancer detection at low prostate specific antigen. J Urol. 2000; 163(3):806-12. View

15.

Catalona W, Smith D, Ratliff T, Dodds K, Coplen D, Yuan J . Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324(17):1156-61. DOI: 10.1056/NEJM199104253241702. View